BioNTech SE (BNTX) Income from Continuing Operations (2018 - 2025)

BioNTech SE has disclosed Income from Continuing Operations across 8 years of filings, most recently posting 174373718.5 for Q4 2025.

• Income from Continuing Operations for Q4 2025 came in at 174373718.5, down 162.88% year-over-year; the trailing twelve-month figure through Dec 2025 was 1056780341.98 (down 32.16% YoY), and the FY2025 annual result was 1090832703.83, down 47.92% from the prior year.
• Income from Continuing Operations came in at 174373718.5 for Q4 2025 at BioNTech SE, down from 91303202.63 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 4151302752.66 in Q1 2022 to a low of 865602233.83 in Q2 2024.
• The 5-year median for Income from Continuing Operations is 406468101.3 (2023), against an average of 1190225217.08.
• Across the five-year window, Income from Continuing Operations jumped 827987404.69% in 2021 and plunged 317.5% in 2024, its largest moves.
• BioNTech SE's Income from Continuing Operations stood at 3622040825.48 in 2021, then grew by 14.54% to 4148835910.98 in 2022, then sank by 88.13% to 492672884.32 in 2023, then slumped by 43.72% to 277300506.34 in 2024, then plunged by 162.88% to 174373718.5 in 2025.
• The last three Income from Continuing Operations figures came in at 174373718.5 (Q4 2025), 91303202.63 (Q3 2025), and 474064717.33 (Q2 2025), per Business Quant data.